Pure Global AI
NCT06280677Recruiting

Aurora Test for ART Donor Patients (AURORA-Donor)

An Observational Study to Evaluate the Expression Profiles of Oocyte-potency-related Genes in Cumulus Cells of Women Treated With Human Recombinant FSH (Hr-FSH)and Triggered With GnRH Agonist in an Oocyte Donation Program
Fertiga, BelgiumClinicalTrials.govother
Verified
Study focus
Disease/Condition
Infertility
Drug/Device/Intervention
AURORA-Donor
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Fertiga, Belgium
Location
Barcelona, Spain
Timeline & enrollment
Phase
N/A
Start date
Feb 16, 2024
End date
Sep 01, 2025
Enrollment
160 participants
Primary outcome

Basic clinical donor patient and stimulation characteristics: P4,Basic clinical donor patient and stimulation characteristics: E2,Basic clinical donor patient and stimulation characteristics: Gonadotropin type and dose,Clinical evaluation: number of Follicles,Clinical evaluation: number of cumulus-oocyte complex,Clinical evaluation: Meiosis II oocytes,Clinical evaluation: Abnormal fertilization,Clinical evaluation: Normal Fertilization,Clinical evaluation: Day 3 embryo evaluation,Clinical evaluation: Day 5/6 embryo evaluation,Clinical evaluation: Day5/6 good quality blastocyst rate,Clinical evaluation: Embryo utilization,Expression profile: blastocyst formation

Summary

This is a randomized observational study. The main aim is to determine potential oocyte
 competence predictive mRNA expression profiles in the cumulus cells isolated form individual
 oocytes. In 2 patient cohorts: 1)GnRH Antagonist & hr-FSH with GnRH Agonist trigger, 2)
 Progesterone & hr-FSH with GnRH Agonist trigger.

ICD-10 classifications
Female infertilityMale infertilityFemale infertility, unspecifiedFemale infertility of other originFemale infertility of uterine origin
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06280677
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06280677 through Pure Global AI's free database. This phase not specified trial is sponsored by Fertiga, Belgium and is currently Recruiting. The study focuses on Infertility. Target enrollment is 160 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.